Staying ahead of the technology curve means strengthening your competitive advantage. That is why we give you data-driven innovation insights into the BioTech industry. This time, you get to discover 5 hand-picked startups developing glycomics solutions.
Global Startup Heat Map highlights 5 Top Glycomics Solutions out of 81
The insights of this data-driven analysis are derived from the Big Data & Artificial Intelligence-powered StartUs Insights Discovery Platform, covering 2.093.000+ startups & scaleups globally. The platform gives you an exhaustive overview of emerging technologies & relevant startups within a specific field in just a few clicks.
The Global Startup Heat Map below reveals the distribution of the 81 exemplary startups & scaleups we analyzed for this research. Further, it highlights 5 BioTech startups that we hand-picked based on criteria such as founding year, location, funding raised, and more. You get to explore the solutions of these 5 startups & scaleups in this report. For insights on the other 76 glycomics solutions, get in touch.
Click to download
Asparia Glycomics provides Glycan Quantification
Changes in the glycome are linked to the development of diseases such as autoimmune diseases, inflammatory conditions, and cancer. Moreover, their structural and chemical properties make them useful for other applications in biofuels, food, and materials. However, the glycome is more complex than the genome or the proteome. This is why BioTech startups are developing solutions to quantify glycans.
Spanish startup Asparia Glycomics provides glycan quantification solutions. The startup offers CarboQuant standards, using patented synthetic 13C-labeled N-glycans produced in its lab for absolute glycan quantification by mass spectrometry. It provides broad coverage of N-glycan structures and shows up to 8 Dalton mass gain. The startup’s solutions quantify glycan profiles in biomarker studies and biopharma research.
FluoretiQ develops Bacterial Diagnostics
Bacterial cell walls possess a rich diversity of glycans, many of which are unique to particular bacterial species. BioTech startups and companies are tapping into this diversity to develop highly specific bacterial diagnostics. Glycomics solutions allow researchers to map glycan profiles of different pathogens to build biosensing probes. These bind to the distinctive structures of glycans to enable the rapid detection of bacterial species.
British startup FluoretiQ offers rapid bacterial diagnostic tools. The startup’s solution, NANOPLEX, utilizes epithelial cells coated in glycans. The library of NANOPLEX probes detects the top 5 species implicated in urinary tract infection. When added to biological samples, the probes form glycan-binding complexes with bacteria, enabling rapid detection.
Tacalyx enables Anticancer Therapeutics
A major hurdle in cancer treatment is that most cancers are detected in advanced stages. Since glycomic changes are more dynamic than proteomic or transcriptomic changes, they enable the detection of early onset of cancers. BioTech startups develop solutions that monitor glycosylation in tumor cells. This enables the development of targeted therapeutics that detect and attack tumors.
Tacalyx is a German startup developing anticancer therapeutics. The startup’s solutions target tumor-associated carbohydrate antigens (TACAs), glycans overexpressed in cancer cells. It uses automated glycan assembly (AGA) to generate a diversity of structurally defined TACAs. Tacalyx leverages immunology and oncology knowledge to develop novel therapeutics.
Gnubiotics offers Microbiome Modulators
In recent years, with a greater understanding of the role of the microbiome in human and animal health, startups are looking for ways to modulate the microbiome. However, most approaches are far from precise and risk negatively impacting the host microbiome. Glycomics-based approaches address this limitation since glycans promote the growth of desirable bacteria while limiting harmful bacteria.
Gnubiotics is a Swiss startup that develops glycans as microbiome modulators. The startup’s Glycan Microbiome Modulators (GMM) platform identifies glycans that nurture and restore microbiome diversity. It develops AMObiome, a natural ingredient that improves gut health in animals. The startup is also investigating microbiome modulators for infant nutrition, irritable bowel syndrome (IBS), and skincare.
BCD Bioscience formulates Novel Ingredients
Glycans play crucial roles in all kinds of cells and thereby hold promise for a range of BioTech applications. However, a lack of methods to synthesize custom glycans limits their potential applications. In recent years, developments in glycomics enable the development of pure and chemically defined glycans. This allows BioTech companies to research and develop oligosaccharide pools that provide selective benefits.
US-based startup BCD Bioscience creates novel ingredients for food, agriculture, and biopharma applications. The startup’s proprietary technology breaks down polysaccharides into oligosaccharides. It then assays its oligosaccharides for selective microbial growth, metabolic output, and effect on the gut barrier infection. Lastly, it uses bioinformatics tools and phenotyping screening to pair glycans with single microbial strains.
Discover more BioTech Startups
BioTech startups such as the examples highlighted in this report focus on artificial intelligence, gene sequencing, tissue engineering as well as biomanufacturing. While all of these technologies play a major role in advancing the BioTech industry, they only represent the tip of the iceberg. To explore more technologies, simply get in touch to let us look into your areas of interest. For a more general overview, you can download our free BioTech Innovation Report to save your time and improve strategic decision-making.
